An initiative by the Ministry for Primary Industries (MPI) to connect farmers with scientists is taking off judging by the ...

The Court Theatre is excited to announce a respected arts leader in Christchurch will be its next Chief Executive. Current ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal ...

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to ...

Roche is in-licensing co-development and co-commercialization rights to Denmark’s Zealand Pharma’s long-acting amylin analog, petrelintide, being developed in phase IIb studies for people who ...

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Investing.com -- Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma ...